Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Platinum Pharmaceuticals

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000415 161 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx161product presentations
G56generic molecules
DF9dosage-form groups
TA10therapeutic areas
PKR161current price records
REG107registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage89%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixPlatinum PharmaceuticalsShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/platinum-pharmaceuticalsGenerated 10 Aug 2026CNS & mental health55 · 34%Anti-infectives45 · 28%Respiratory & allergy19 · 12%Cardiovascular17 · 11%Oncology & immunology6 · 4%Vitamins, minerals & nutrition5 · 3%Reproductive & genitourinary5 · 3%Other therapeutic areas9 · 6%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioPlatinum PharmaceuticalsDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/platinum-pharmaceuticalsGenerated 10 Aug 2026161presentationsTablet99 · 61%Capsule17 · 11%Suspension15 · 9%Syrup9 · 6%Inhalation8 · 5%Solution7 · 4%Other forms6 · 4%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionPlatinum PharmaceuticalsCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/platinum-pharmaceuticalsGenerated 10 Aug 2026144comparable productsBelow market median7 · 5%Near market median43 · 30%Above market median94 · 65%Company median price position+9.8%Lowest-price equivalents9Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsPlatinum PharmaceuticalsCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/platinum-pharmaceuticalsGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,34 shared61% overlapMediate Pharmaceutical Pvt Ltd31 shared55% overlapCCL Pharmaceuticals (Pvt.) Ltd.30 shared54% overlapBio-Labs(Pvt) Ltd29 shared52% overlapGenome Pharmaceuticals (Pvt.) Ltd,29 shared52% overlapWerrick Pharmaceuticals28 shared50% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

CNS & mental health55 products · 34%
Anti-infectives45 products · 28%
Respiratory & allergy19 products · 12%
Cardiovascular17 products · 11%
Oncology & immunology6 products · 4%
Vitamins, minerals & nutrition5 products · 3%
Reproductive & genitourinary5 products · 3%
Hematology & thrombosis4 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antiepileptics31 products · 19%
Antipsychotics12 products · 7%
Antimalarials12 products · 7%
Antihistamines11 products · 7%
Macrolide antibacterials10 products · 6%
Beta blockers8 products · 5%
SSRI antidepressants8 products · 5%
Immunosuppressants / immunomodulators6 products · 4%
Formulation footprint

Dosage forms

Tablet99 products
Capsule17 products
Suspension15 products
Syrup9 products
Inhalation8 products
Solution7 products
Cream2 products
Pessary2 products
Sachet2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 LEVOTAMLevetiracetam 11presentations 1 g, 100 MG/mL, 100 mg/mL, 250 mg · Tablet, Solution #2 SEIZUNILCarbamazepine 9presentations 100 mg/5 mL, 200 mg, 400 MG, 400 mg · Suspension, Tablet #3 FEXOFASTFexofenadine 7presentations 120 mg, 180 mg, 30 mg/5 mL, 30 MG/5 mL · Tablet, Solution #4 PLAZOAzithromycin 7presentations 200 mg/5 mL, 250 MG, 500 mg, 500 MG · Suspension, Tablet #5 ARIPAAripiprazole 6presentations 10 mg, 15 mg · Tablet #6 CARDAXENAtenolol 5presentations 100 mg, 25 mg, 50 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median75% of comparable products
Near market median43within ±5% of median
Above market median9465% of comparable products
Lowest-price equivalents9ties included
Company median price position +9.8% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Empanum 10 mgEmpagliflozin · Tablet · 2x7's PKR 46.43/tablet-43.8% vs market median BLICOR 10 mgBisoprolol fumarate · Tablet · 2x10's PKR 14.85/tablet-32.9% vs market median BlicorTablet 2.5 mgBisoprolol fumarate · Tablet · 14's PKR 3.22/tablet-24.3% vs market median CITALO 20 mgCitalopram · Tablet · 10'S PKR 41.07/tablet-22.4% vs market median BlicorTablet 2.5 mgBisoprolol fumarate · Tablet · 10's PKR 3.32/tablet-21.9% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 34shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 31shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 30shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 29shared generics Genome Pharmaceuticals (Pvt.) Ltd,149 products · 71 generics 29shared generics Werrick Pharmaceuticals249 products · 82 generics 28shared generics
Regulatory & price activity

Observed database signals

Registration numbers107
Price-history records219
Products with price history41
Source records with multiple versions6
Latest MedInfoBase verification10 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

31 results
Intelligence filter: Drug classAntiepileptics Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
DAPAKAN Sodium valproate 250 mg/5 mL Syrup 120ml 024466 PKR 220.04 PKR 1.83/mL Near median
DAPAKAN Divalproex sodium 500 mg Tablet 100'S 024465 PKR 1,323.73 PKR 13.24/tablet 11% above median
DAPAKAN Divalproex sodium 500 mg Tablet 20'S 024465 PKR 270.22 PKR 13.51/tablet 14% above median
DAPAKAN Divalproex sodium 250 mg Tablet 100'S 024464 PKR 847.74 PKR 8.48/tablet 14% above median
DAPAKAN Divalproex sodium 250 mg Tablet 30'S 024464 PKR 254.32 PKR 8.48/tablet 14% above median
DAPAKAN Sodium valproate 250 MG/5 mL Syrup 60ml 024466 PKR 110.02 PKR 1.83/mL Near median
DAPAKAN Sodium valproate 250 MG /5 mL Syrup 300ml 024466 PKR 539.11 PKR 1.80/mL No comparator
DAPAKAN Sodium valproate 250 mg/5 mL Syrup 250ml 024466 PKR 449.25 PKR 1.80/mL Near median
LAMONIL Lamotrigine = 25 mg Tablet 30'S 035604 PKR 648.66 PKR 21.62/tablet Near median
LAMONIL Lamotrigine = 100 mg Tablet 30'S 036299 PKR 1,081.10 PKR 36.04/tablet Near median
LAMONIL Lamotrigine = 50 mg Tablet 30'S 035605 PKR 864.88 PKR 28.83/tablet Near median
LEVOTAM Levetiracetam 250 mg Tablet 30'S 053129 PKR 2,199.56 PKR 73.32/tablet 33% above median
LEVOTAM Levetiracetam 100 mg/mL Oral solution 60 ML 070837 PKR 739.33 PKR 12.32/mL 9% below median
LEVOTAM Levetiracetam 500 MG Tablet 10'S 053046 PKR 1,215.68 PKR 121.57/tablet 29% above median
LEVOTAM Levetiracetam 1 g Tablet 30's 055642 PKR 5,363.27 PKR 178.78/tablet 39% above median
LEVOTAM Levetiracetam 100 mg/mL Oral solution 60ml 070837 PKR 887.62 PKR 14.79/mL 10% above median
LEVOTAM Levetiracetam 750 mg Tablet 30'S 055641 PKR 4,290.62 PKR 143.02/tablet 9% above median
LEVOTAM Levetiracetam 250 mg Tablet 10'S 053129 PKR 733.18 PKR 73.32/tablet 33% above median
LEVOTAM Levetiracetam 500 mg Tablet 30'S 053046 PKR 3,647.03 PKR 121.57/tablet 29% above median
LEVOTAM Levetiracetam 100 MG/mL Oral solution 120ml 070837 PKR 1,775.41 PKR 14.80/mL 10% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.